Back to Registry

Selank

Also known as: TP-7, Tuftsin Analog, Selank Diacetate

Research Only

Molecular Formula

C33 H57 N11 O9 Fr Ba

Molecular Weight

751.87 Da (Free Base; Diacetate ~871.98 Da)

Half-Life

Unknown in human circulation (rapid nasal absorption reported; plasma concentration declines within ~5–5.5 minutes in Russian product data)

Sequence

Thr-Lys-Pro-Arg-Pro-Gly-Pro

Clinical Applications & Evidence

Mechanism of Action

In preclinical and animal models, Selank modulates GABAergic ligand binding and gene expression, inhibits enkephalin-degrading enzymes (enkephalinases), upregulates BDNF mRNA expression in the rat hippocampus, and influences ex-vivo cytokine expression. Clinically established single molecular targets in humans remain under investigation.

Investigated Uses

  • Generalized anxiety & neurasthenia (Investigational / Russian Approved Drug — 62-patient Russian comparative trial with medazepam; unproven in large multinational trials)
  • Cognitive & functional brain connectivity (Preclinical rodent models & small 2020 human neuroimaging connectomics study)
  • Immunomodulatory biomarker research (Preclinical & small human ex-vivo cytokine gene-expression study; unproven clinical immune support)
  • PTSD & depressive symptoms (Preclinical rodent models; unproven for major depressive disorder in controlled human trials)
Early Clinical / Animal Models

Regulatory & Safety Status

FDA Status

Research Only

WADA / Athletic Status

Not Explicitly Prohibited

Known Side Effects

Unpleasant taste if solution drains into the pharynx (reported in product labeling)Localized nasal mucosal irritation or burningAllergic reactions or individual hypersensitivityLong-term safety profile and non-Russian clinical trial datasets remain limited

Contraindications

  • Pregnancy and lactation (Contraindicated in Russian product labeling; unstudied safety profile)
  • Pediatric populations under 18 years of age (Safety and efficacy unestablished)
  • Known hypersensitivity to tuftsin derivatives or formulation excipients

Drug Interactions

  • Centrally acting anxiolytics and sedatives (Theoretical additive CNS overlap; unstudied in formal interaction trials)
  • Immunomodulatory therapies (Theoretical overlap; clinical drug interactions have not been systematically studied)

Citations & Clinical Trials

PubMed Comparative Efficacy of Selank and Medazepam in Generalized Anxiety Disorder (2008) PubMed Effect of Selank on Functional Connectivity of the Human Brain (2020) Europe PMC Selank Modulation of BDNF Expression in Rat Hippocampus (2008) Europe PMC Ex Vivo Cytokine Gene Expression Modulation by Selank (2008) Medvestnik / Russian Ministry of Health Russian State Register of Medicines: Selank 0.15% Intranasal Solution (LSR-003338/09) FDA FDA Compounding Safety Assessment: Certain Bulk Drug Substances Presenting Risks